Prostate Volume and PSA Cutoff Values as Predictive Indices for Success of Doxazocin Treatment in BPH in GHRDS
الملخص
Background: Benign prostatic hyperplasia (BPH) is a non malignant enlargement of the prostate.
This study was conducted to determine the pattern of presentation of BPH with and without acute
urinary retention (AUR) and to determine the risk factors for acute urinary retention, in addition, to
assess the results of doxazosin in the treatment of BPH with and without AUR.
Patients and methods: Ninety two patients were enrolled in this study. All patients presented to
the emergency department and the referred clinic of the Gezira Hospital for Renal Disease and
Surgery (GHRDS) with lower urinary tract symptoms with and without acute urinary retention
suggestive of BPH were evaluated according to the European guidelines. All of them underwent
trans-rectal ultra sound and measurement for the prostatic volume. Serum PSA level was estimated.
Doxazosin was given to all patients and they were followed for twelve weeks. A trial without a
catheter at the end of the first week was attempted for patients with acute urinary retention.
Results: The patients’ mean age ± SD at baseline was 67.8 ± 7.7 and 69.4 ± 9.9 for Non-AUR/BPH
and AUR/BPH respectively. Comparing baseline clinical parameters of patients with and without
acute urinary retention revealed that IPSS, prostate volume and PSA level are significantly different
between the two groups with P< 0.01, 0.01 and 0.00 respectively. In the TWOC, 65% of patients
passed urine spontaneously. By the end of the study, the overall response of patients showed 78.9%
successful rate (n=73) and 21.1% failure rate (n=19). Prostatic volume and PSA level were found to
affect doxazosin treatment significantly. With cutoff values of 41cc and (3.45) ng/ml, prostatic
volume and PSA level influenced doxazosin treatment failure.
Conclusion: Serum PSA and prostate volume are powerful predictors of the risk of AUR. Alpha
blockers are efficacious in treating retaining and non-retaining BPH patients. Knowledge of
baseline serum PSA and/or prostate volume are useful tools to aid physicians and decision makers
in predicting the risk of BPH-related outcomes and choosing dexazosin as therapy for BPH.
المراجع
Bosch JL, Hop WGJ, Kirkles WJ et al. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. Urology 1995;46: 34-40.
Barry MJ, Fowler FJ Jr, Bin L, et al. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 1997;157: 10–15.
Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158: 481–487.
Guess HA: Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev1992; 14: 131–153.
Roehrborn CG, McConnell JD, Lieber M, et al. Serum prostate-specific antigen is a powerful predictor of acute urinary retention and the need for surgery in men with clinical benign prostatic hyperplasia. Urology1999; 53: 473–480.
Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate-specific antigen and prostate volume predict long term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. Urology 1999;54: 662–669.
Marberger MJ, Andersen JT, Nickel JC, et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Eur Urol 2000;38: 563–568.
Kaplan S, Garvin D, Gilhooly P, et al, for the PLESS Study Group: Impact of baseline symptom severity on future risk of benign prostatic hyperplasiarelated outcomes and long-term response to finasteride. Urology2000; 56: 610–616.
Roehrborn CG, McConnell JD, Saltzman B, et al. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol 2002;42: 1-6.
Lepor H, Williford WU, Barry MJ, et al. The impact of medical therapy on bother dies to symptoms, quality of life and global outcome and factors predicting response. Veterans affairs cooperative studies benign prostatic hyperplasia study group. J Urol 1998;160: 1358-67.
Hartung R. Do alpha blockers prevent the occurrence of acute urinary retention? Eur Urol 2001; 39:13-8.
Roehrborn CG, Boyle P, Gould AL, et al. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999;53: 581–589.
Christopher R Chapple. A comparison of varying alpha blockers and other pharmacotherapy options for lower urinary tract symptoms. Rev Urol 2005;7: 22-30.
Sung JH, WOO JK, Sun K et al. Identification of baseline clinical factors which predicts medical treatment failure of benign prostatic hyperplasia: an observational cohort study. Eur Urol 2003;44: 94-100.
Mariapan P, Brown D, McNeill A. Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: A prospective clinical study. J Urol 2007;178 (2): 573-77.
Tan YH, Foo KT. Intravesical prostate protrusion predicts the outcome of a trial without catheter following acute urine retention. J Urol 2003;170: 2339-41.
McNeill AS, Rizvi S, Byrne DJ. Prostate size influences the outcome after presenting with acute urinary retention. BJU Int 2004;94 (4): 559-62.
Fawzy A, Braun K, Lewis GP, Gaffney M, et al, Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study. J Urol 154: 105-109, 1995.
Milonas D, Trumbeckas D. PSA and transition zone index- powerful predictors for AUR in men with BPH. Medicina (Kaunas) 2003;39 (11): 1071-7.
Kurita Y, Masuda H, Suzuki K et al. Tranzition zone ratio and PSAD as predictors for the response of BPH to alpha blockers and anti- androgen therapy. Br J Urol 1997;80 (1): 78-83.
